TY - JOUR
T1 - A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival
AU - Hoehn, Richard S.
AU - Rieser, Caroline J.
AU - Winters, Sharon
AU - Stitt, Lauren
AU - Hogg, Melissa E.
AU - Bartlett, David L.
AU - Lee, Kenneth K.
AU - Paniccia, Alessandro
AU - Ohr, James P.
AU - Gorantla, Vikram C.
AU - Krishnamurthy, Anuradha
AU - Rhee, John C.
AU - Bahary, Nathan
AU - Olson, Adam C.
AU - Burton, Steve
AU - Ellsworth, Susannah G.
AU - Slivka, Adam
AU - McGrath, Kevin
AU - Khalid, Asif
AU - Fasanella, Kenneth
AU - Chennat, Jennifer
AU - Brand, Randal E.
AU - Das, Rohit
AU - Sarkaria, Ritu
AU - Singhi, Aatur D.
AU - Zeh, Herbert J.
AU - Zureikat, Amer H.
N1 - Funding Information:
This study was funded by the Division of Surgical Oncology at the, University of Pittsburgh Medical Center.
Publisher Copyright:
© 2021, Society of Surgical Oncology.
PY - 2021/5
Y1 - 2021/5
N2 - Aims: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on patient SES and to study the role of a multidisciplinary clinic (MDC) in mitigating any variations. Methods: The study analyzed patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in a large hospital system. The patients were categorized into groups of high and low SES and whether they were managed by the authors’ pancreatic cancer MDC or not. The study compared differences in disease characteristics, receipt of multimodality therapy, perioperative outcomes, and recurrence-free and overall survival. Results: Of the 162 low-SES patients and 119 high-SES patients, 54% were managed in the MDC. Outside the MDC, low-SES patients were less likely to receive neoadjuvant chemotherapy and had less minimally invasive surgery, a longer OR time, less enhanced recovery participation, and more major complications (p < 0.05). No SES disparities were observed among the MDC patients. Despite similar tumor characteristics, the low-SES patients had inferior median overall survival (21 vs 32 months; p = 0.005), but the MDC appeared to eliminate this disparity. Low SES correlated with inferior survival for the non-MDC patients (17 vs 32 months; p < 0.001), but not for the MDC patients (24 vs 25 months; p = 0.33). These findings persisted in the multivariable analysis. Conclusion: A pancreatic cancer MDC standardizes treatment decisions, eliminates disparities in surgical outcomes, and improves survival for low-SES patients.
AB - Aims: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on patient SES and to study the role of a multidisciplinary clinic (MDC) in mitigating any variations. Methods: The study analyzed patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma in a large hospital system. The patients were categorized into groups of high and low SES and whether they were managed by the authors’ pancreatic cancer MDC or not. The study compared differences in disease characteristics, receipt of multimodality therapy, perioperative outcomes, and recurrence-free and overall survival. Results: Of the 162 low-SES patients and 119 high-SES patients, 54% were managed in the MDC. Outside the MDC, low-SES patients were less likely to receive neoadjuvant chemotherapy and had less minimally invasive surgery, a longer OR time, less enhanced recovery participation, and more major complications (p < 0.05). No SES disparities were observed among the MDC patients. Despite similar tumor characteristics, the low-SES patients had inferior median overall survival (21 vs 32 months; p = 0.005), but the MDC appeared to eliminate this disparity. Low SES correlated with inferior survival for the non-MDC patients (17 vs 32 months; p < 0.001), but not for the MDC patients (24 vs 25 months; p = 0.33). These findings persisted in the multivariable analysis. Conclusion: A pancreatic cancer MDC standardizes treatment decisions, eliminates disparities in surgical outcomes, and improves survival for low-SES patients.
UR - http://www.scopus.com/inward/record.url?scp=85100132585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100132585&partnerID=8YFLogxK
U2 - 10.1245/s10434-021-09594-8
DO - 10.1245/s10434-021-09594-8
M3 - Article
C2 - 33523364
AN - SCOPUS:85100132585
SN - 1068-9265
VL - 28
SP - 2438
EP - 2446
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 5
ER -